Based on the data available, retatrutide has produced a larger average weight-loss effect than mazdutide at their respective top doses roughly 28% versus roughly 17% over comparable multi-month periods which is consistent with retatrutides third mechanism of action on top of the GLP-1/glucagon combination that both compounds share
Adequate protein intake is the primary mitigation strategy
Melanocytic lesions, such as blue nevi, are more common on the palate
Where patient-level incidence was available, the proportion with 1 AE ranged from 035% in treatment arms and 1046% in controls
What women on HRT should know before starting GLP-1s If youre currently on HRT and considering adding a GLP-1 RA, your care team will evaluate the following: Muscle preservation strategy : Menopause naturally accelerates lean muscle loss, and rapid weight loss compounds this issue
limited to 8 doses/month Injection site : Reactions at the injection site with the subcutaneous autoinjector While both compounds share melanocortin-related side effects, PT-141's narrower receptor profile and regulated dosing provide a more controlled risk-benefit profile